Radial Raises $50M Series A to Expand Access to Advanced Mental Health Treatments

Radial, a New York–based company focused on expanding access to advanced mental health treatments, has raised $50 million in a Series A funding round to grow its clinical network, technology infrastructure, and national reach. The financing marks a major milestone for the startup as it works to bring modern interventional psychiatry services—such as neuromodulation and rapid‑acting therapeutics—into broader clinical practice and make them more accessible to patients across the United States.

The $50 million Series A round was led by General Catalyst, with participation from Solari Capital, JSL Health Capital, Founder Collective, BoxGroup, Scrub Capital, and investor Diede van Lamoen. This broad syndicate reflects strong confidence in Radial’s approach to modernizing mental healthcare access and delivery.

Founded in 2023 by CEO John Capecelatro and other leaders with deep experience in healthcare operations and technology, Radial has built a proprietary platform combining clinical infrastructure, reimbursement tools, and decision support tailored to high‑impact brain medicine. The company’s model focuses on evidence‑based treatments such as accelerated transcranial magnetic stimulation (TMS) and rapid‑acting medications like esketamine, therapies that have demonstrated faster and more meaningful outcomes for certain mental health conditions compared with traditional approaches. Radial’s tools aim to help clinicians deliver these treatments efficiently while helping insurers better understand and reimburse for care that delivers measurable results.

Radial currently operates seven clinics across six U.S. states, all supported by its proprietary software platform, which helps streamline clinical workflows, insurance verification, and treatment planning. Its clinics accept most major insurance plans, including Medicare, Tricare, VA‑CCN, Aetna, Cigna, UnitedHealthcare, and many Blues plans, enabling patients to access advanced therapies without relying on limited cash‑pay models that have historically restricted access to interventional psychiatry. The Series A funds are expected to support the company’s national expansion plan throughout 2026, increasing both its clinic footprint and partnerships with technology and care delivery organizations.

Radial’s funding comes at a time when mental health care continues to face significant challenges, including limited access to effective treatments, long wait times for care, and reimbursement barriers that discourage broader adoption of evidence‑based interventions. The company’s leaders argue that many modern therapies can deliver substantial relief in days or weeks—far faster than traditional medication‑only models that often require months of trial‑and‑error adjustments—and that systemic infrastructure and operational tools are needed to bring these innovations to scale. With its newly raised capital, Radial aims to build that infrastructure and reduce the friction patients and providers face when trying to implement advanced psychiatric care.

Investors have expressed confidence in Radial’s ability to bridge the gap between clinical research and real‑world treatment adoption. Partners at lead investor General Catalyst highlighted the company’s strong team and mission as key drivers of its potential to expand access to transformative mental health care. The participation of investors focused on healthcare and technology reflects broader interest in scalable models that blend clinical excellence with data‑driven operations.

As part of its growth strategy, Radial also plans to continue developing its software and reimbursement support tools to help clinicians and payers navigate complex insurance pathways and build sustainable clinical workflows. By focusing on both care delivery and the economic structures that enable it, the company hopes to establish a more effective model for interventional psychiatry and improve outcomes for people living with serious mental health conditions.

With the new funding, Radial is positioning itself to play a significant role in the ongoing transformation of mental health care in the United States. By expanding its clinical network, investing in technology, and deepening its engagement with payers, the company aims to make advanced brain medicine accessible to a broader population and support a shift toward outcome‑driven psychiatric care that can address the urgent needs of patients and families nationwide.